pioglitazone has been researched along with Atherogenesis in 70 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study." | 9.15 | Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression o ( Bayturan, O; Kupfer, S; Lavoie, A; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Tuzcu, EM; Uno, K; Wolski, K, 2011) |
| "These results suggest that pioglitazone treatment reduces the progression of carotid IMT and improves insulin resistance in renal allograft recipients without a history of diabetes." | 9.14 | Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients. ( Cha, BS; Choi, SH; Han, SJ; Hur, KY; Kang, ES; Kim, DJ; Kim, MS; Kim, SI; Kim, YS; Kwak, JY; Lee, HC, 2010) |
| "The aim of this study was to investigate the effects of pioglitazone or metformin on bone mass and atherosclerosis in patients with type 2 diabetes." | 9.14 | Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. ( Kanazawa, I; Kurioka, S; Sugimoto, T; Yamaguchi, T; Yamamoto, M; Yamauchi, M; Yano, S, 2010) |
| " Pioglitazone treatment reduced sCD36 while improving insulin-stimulated glucose metabolism, further supporting the association between sCD36 and insulin resistance in PCOS." | 9.13 | Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Handberg, A; Henriksen, JE; Højlund, K, 2008) |
| "In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride." | 9.13 | Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. ( De Larochellière, R; Hu, B; Jure, H; Kupfer, S; Lincoff, AM; Mavromatis, K; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Saw, J; Staniloae, CS; Tuzcu, EM; Wolski, K, 2008) |
| "The purpose of this research was to evaluate the short-term effects of pioglitazone (PIO) on high-density lipoprotein cholesterol (HDL-C) and other metabolic parameters in nondiabetic patients with metabolic syndrome (MetSyn)." | 9.12 | Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. ( Bloedon, LT; Chittams, J; Duffy, D; Rader, DJ; Reilly, MP; Samaha, FF; Soffer, D; Szapary, PO; Wolfe, ML, 2006) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 7.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| "This paper aims to investigate the interaction mechanism between pioglitazone/simvastatin and the CD40-CD40 ligand (CD40-CD40L) system and to determine their interaction effects on atherosclerosis in rabbits." | 7.81 | Effect of pioglitazone combined with simvastatin on the CD40-CD40 ligand system in rabbits with atherosclerosis. ( Bao, XC; Gao, XQ; Ji, XP; Li, HW; Qiu, YH; Wu, Z; Xue, L; Yang, XF; Zhu, XH, 2015) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| " To assess the contribution of SMC-specific PPARγ in ligand-mediated attenuation of Ang II-induced atherosclerosis and AAAs, both male and female Cre(0/0) and Cre(+/0) mice were fed a fat-enriched diet with or without the PPARγ agonist pioglitazone (Pio) (20 mg/kg per day) for 5 weeks." | 7.76 | Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}. ( Bruemmer, D; Daugherty, A; Golledge, J; Ijaz, T; Subramanian, V, 2010) |
| "Pioglitazone and rosiglitazone enhanced macrophage apoptosis by a number of stimuli, including those thought to be important in advanced atherosclerosis." | 7.74 | Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. ( Gonzalez, FJ; Kuriakose, G; Shah, YM; Tabas, I; Thorp, E, 2007) |
| "Atherosclerosis was induced via a high-cholesterol diet and endothelial denudation." | 5.48 | Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An ( Feng, T; Li, J; Nie, M; Xu, J; Xu, Z; Yan, Y; Zhang, M; Zhao, Q; Zhao, X, 2018) |
| "Inflammation is an essential component of vulnerable or high-risk atheromas." | 5.37 | Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. ( Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Roytman, M; Rudd, JH; Tsimikas, S; Vucic, E, 2011) |
| "Pioglitazone treatment of atherogenic mice prevented this progression of atherosclerosis from its middle stages of disease, but was not able to reverse it." | 5.35 | Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. ( Gotto, AM; Hajjar, DP; Han, J; Nakaya, H; Nicholson, AC; Summers, BD, 2009) |
| "In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study." | 5.15 | Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression o ( Bayturan, O; Kupfer, S; Lavoie, A; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Tuzcu, EM; Uno, K; Wolski, K, 2011) |
| "These results suggest that pioglitazone treatment reduces the progression of carotid IMT and improves insulin resistance in renal allograft recipients without a history of diabetes." | 5.14 | Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients. ( Cha, BS; Choi, SH; Han, SJ; Hur, KY; Kang, ES; Kim, DJ; Kim, MS; Kim, SI; Kim, YS; Kwak, JY; Lee, HC, 2010) |
| "The aim of this study was to investigate the effects of pioglitazone or metformin on bone mass and atherosclerosis in patients with type 2 diabetes." | 5.14 | Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. ( Kanazawa, I; Kurioka, S; Sugimoto, T; Yamaguchi, T; Yamamoto, M; Yamauchi, M; Yano, S, 2010) |
| " Pioglitazone treatment reduced sCD36 while improving insulin-stimulated glucose metabolism, further supporting the association between sCD36 and insulin resistance in PCOS." | 5.13 | Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Handberg, A; Henriksen, JE; Højlund, K, 2008) |
| "These results strongly suggested that treatment with pioglitazone has a greater clinical benefit for the prevention of atherosclerosis, including coronary heart diseases, without any adverse side-effects." | 5.13 | Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. ( Hirata, A; Igarashi, M; Jimbu, Y; Tominaga, M; Yamaguchi, H, 2008) |
| "In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride." | 5.13 | Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. ( De Larochellière, R; Hu, B; Jure, H; Kupfer, S; Lincoff, AM; Mavromatis, K; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Saw, J; Staniloae, CS; Tuzcu, EM; Wolski, K, 2008) |
| "The purpose of this research was to evaluate the short-term effects of pioglitazone (PIO) on high-density lipoprotein cholesterol (HDL-C) and other metabolic parameters in nondiabetic patients with metabolic syndrome (MetSyn)." | 5.12 | Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. ( Bloedon, LT; Chittams, J; Duffy, D; Rader, DJ; Reilly, MP; Samaha, FF; Soffer, D; Szapary, PO; Wolfe, ML, 2006) |
| "Pioglitazone may influence CVD pathophysiology at multiple points in the disease process, including atherogenesis, plaque inflammation, plaque rupture and haemostatic disturbances (i." | 4.86 | Pioglitazone and mechanisms of CV protection. ( Erdmann, E; Wilcox, R, 2010) |
| " Available data suggest that pioglitazone can delay progression of atherosclerosis in patients with type 2 diabetes, as shown by the PERISCOPE and CHICAGO studies, and that it can reduce the rate of clinical CV events as shown by PROactive." | 4.85 | Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. ( Fisher, M, 2009) |
| "Thirty rabbits were randomly divided into an atherosclerosis group, an atorvastatin group, and an atorvastatin plus pioglitazone group." | 4.12 | Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model. ( Chen, X; Liang, Z; Nie, M; Yan, Y; Zhang, X; Zhao, Q, 2022) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 3.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "This paper aims to investigate the interaction mechanism between pioglitazone/simvastatin and the CD40-CD40 ligand (CD40-CD40L) system and to determine their interaction effects on atherosclerosis in rabbits." | 3.81 | Effect of pioglitazone combined with simvastatin on the CD40-CD40 ligand system in rabbits with atherosclerosis. ( Bao, XC; Gao, XQ; Ji, XP; Li, HW; Qiu, YH; Wu, Z; Xue, L; Yang, XF; Zhu, XH, 2015) |
| " Here, we tested the effect of a potent and selective peroxisome proliferator-activated receptor-γ agonist, rivoglitazone (Rivo), a newly synthesized thiazolidinedione derivative, on adiponectin, insulin resistance, and atherosclerosis." | 3.77 | Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone. ( Funahashi, T; Hirata, A; Hiuge-Shimizu, A; Kihara, S; Maeda, N; Nakamura, K; Nakatsuji, H; Okuno, A; Shimomura, I, 2011) |
| " The aim of this study was to investigate the relationship between accelerated atherosclerosis (AS) and the balance of regulatory/effector T cells (Treg/Teff) in uremic apolipoprotein E knockout (apoE-/-) mice, and the effect of pioglitazone on uremic AS and possible mechanisms." | 3.77 | Antiatherogenic effect of pioglitazone on uremic apolipoprotein E knockout mice by modulation of the balance of regulatory and effector T cells. ( Chen, T; Kishimoto, C; Liang, X; Liu, W; Liu, Y; Shen, Y; Tian, Y; Wang, L; Wu, Y; Xiao, Y; Yin, A; Yuan, Z; Zhao, Y, 2011) |
| " To assess the contribution of SMC-specific PPARγ in ligand-mediated attenuation of Ang II-induced atherosclerosis and AAAs, both male and female Cre(0/0) and Cre(+/0) mice were fed a fat-enriched diet with or without the PPARγ agonist pioglitazone (Pio) (20 mg/kg per day) for 5 weeks." | 3.76 | Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}. ( Bruemmer, D; Daugherty, A; Golledge, J; Ijaz, T; Subramanian, V, 2010) |
| "Pioglitazone inhibits aortic atherosclerosis in ApoE-/- mice, and these effects are correlated with increased plasma adiponectin level and the expression of AdipoR1 mRNA in vessels." | 3.75 | [Role of adiponectin and its receptors in anti-atherosclerotic effects of pioglitazone on ApoE knocked out mice]. ( Chen, LZ; Da-Wa, CR; Huo, Y; Qi, YF; Zhao, F, 2009) |
| "Pioglitazone and rosiglitazone enhanced macrophage apoptosis by a number of stimuli, including those thought to be important in advanced atherosclerosis." | 3.74 | Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. ( Gonzalez, FJ; Kuriakose, G; Shah, YM; Tabas, I; Thorp, E, 2007) |
| "Atorvastatin treatment, alone and in combination with pioglitazone, revealed a significant regression in IMT (0." | 2.73 | Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. ( Forst, T; Fuchs, W; Hanefeld, M; Konrad, T; Lehmann, U; Müller, J; Pfützner, A; Schaper, F; Weber, M; Wilhelm, B, 2008) |
| "Pioglitazone treatment reduced insulin, FFA, and C-reactive protein concentrations compared with placebo (18." | 2.71 | Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. ( de Koning, EJ; Martens, FM; Rabelink, TJ; Visseren, FL, 2005) |
| "Type 2 diabetes has long been recognized as an independent risk factor for cardiovascular disease (CVD), including coronary artery disease (CAD), stroke, peripheral arterial disease, cardiomyopathy, and congestive heart failure." | 2.47 | Macrovascular effects and safety issues of therapies for type 2 diabetes. ( Plutzky, J, 2011) |
| "Pioglitazone treatment of atherogenic mice prevented this progression of atherosclerosis from its middle stages of disease." | 2.46 | [Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice]. ( Nakaya, H, 2010) |
| "Type 2 diabetes mellitus is usually accompanied by concomitant disorders, such as dyslipidemia, hypertension and atherosclerosis." | 2.44 | Pleiotropic effects of thiazolidinediones. ( Elisaf, MS; Liberopoulos, EN; Mikhailidis, DP; Rizos, CV, 2008) |
| "Insulin resistance is associated with inflammation and has a key role in atherogenesis." | 2.43 | Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. ( Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R, 2006) |
| "Atherosclerosis is one of the most urgent global health subjects, causes millions of deaths worldwide, and is associated with enormous healthcare costs." | 1.91 | Encapsulation of Pioglitazone into Polymer-Nanoparticles for Potential Treatment of Atherosclerotic Diseases. ( Breunig, M; Fleischmann, D; Goepferich, AM; Groner, J; Mietzner, R; Tognazzi, M; Walter, M; Ziegler, CE, 2023) |
| "Atherosclerosis was induced via a high-cholesterol diet and endothelial denudation." | 1.48 | Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An ( Feng, T; Li, J; Nie, M; Xu, J; Xu, Z; Yan, Y; Zhang, M; Zhao, Q; Zhao, X, 2018) |
| "Type 2 diabetes is often associated with arterial atherosclerosis in large blood vessels." | 1.46 | Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients. ( Chen, W; Liu, X; Mei, T; Ye, S, 2017) |
| "Leoligin is a natural lignan found in Edelweiss (Leontopodium nivale ssp." | 1.43 | Leoligin, the Major Lignan from Edelweiss (Leontopodium nivale subsp. alpinum), Promotes Cholesterol Efflux from THP-1 Macrophages. ( Atanasov, AG; Dirsch, VM; Heiss, EH; Hošek, J; Ladurner, A; Latkolik, S; Linder, T; Mihovilovic, MD; Palme, V; Polanský, O; Schilcher, N; Schwaiger, S; Stangl, H; Stuppner, H; Wang, L, 2016) |
| "Inflammation is an essential component of vulnerable or high-risk atheromas." | 1.37 | Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. ( Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Roytman, M; Rudd, JH; Tsimikas, S; Vucic, E, 2011) |
| "Pioglitazone has an important role in the treatment of patients with Type 2 diabetes." | 1.37 | Which is the eligible patient to be treated with pioglitazone? The expert view. ( Avogaro, A; Betteridge, J; Bonadonna, R; Campbell, IW; Crepaldi, G; Farinaro, E; Federici, M; Schernthaner, GH; Staels, B, 2011) |
| "Pioglitazone treatment of atherogenic mice prevented this progression of atherosclerosis from its middle stages of disease, but was not able to reverse it." | 1.35 | Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. ( Gotto, AM; Hajjar, DP; Han, J; Nakaya, H; Nicholson, AC; Summers, BD, 2009) |
| "Fenofibrate treatment significantly improved lipoprotein metabolism toward a less atherogenic phenotype but did not affect insulin sensitivity." | 1.33 | PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. ( Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G, 2005) |
| "Pioglitazone is an agonist of the peroxisome proliferator-activated receptor gamma (PPARgamma) that raises HDL-cholesterol plasma in humans." | 1.33 | Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit. ( Cardoso-Saldaña, G; Carreón-Torres, E; Fievet, C; Franco, M; Gómez, CH; Juárez-Meavepeña, M; Juárez-Oropeza, MA; Luc, G; Pérez-Méndez, O, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 36 (51.43) | 29.6817 |
| 2010's | 31 (44.29) | 24.3611 |
| 2020's | 3 (4.29) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, L | 3 |
| Ladurner, A | 1 |
| Latkolik, S | 1 |
| Schwaiger, S | 1 |
| Linder, T | 1 |
| Hošek, J | 1 |
| Palme, V | 1 |
| Schilcher, N | 1 |
| Polanský, O | 1 |
| Heiss, EH | 1 |
| Stangl, H | 1 |
| Mihovilovic, MD | 1 |
| Stuppner, H | 1 |
| Dirsch, VM | 1 |
| Atanasov, AG | 1 |
| Zhang, X | 1 |
| Chen, X | 1 |
| Liang, Z | 1 |
| Nie, M | 2 |
| Yan, Y | 2 |
| Zhao, Q | 2 |
| Groner, J | 1 |
| Tognazzi, M | 1 |
| Walter, M | 1 |
| Fleischmann, D | 1 |
| Mietzner, R | 1 |
| Ziegler, CE | 1 |
| Goepferich, AM | 1 |
| Breunig, M | 1 |
| Wu, Y | 4 |
| Zhang, Y | 1 |
| Dai, L | 1 |
| Wang, Q | 1 |
| Xue, L | 2 |
| Su, Z | 1 |
| Zhang, C | 1 |
| Connelly, MA | 1 |
| Velez Rivera, J | 1 |
| Guyton, JR | 1 |
| Siddiqui, MS | 1 |
| Sanyal, AJ | 1 |
| Liu, X | 1 |
| Mei, T | 1 |
| Chen, W | 1 |
| Ye, S | 1 |
| Xu, J | 1 |
| Li, J | 1 |
| Xu, Z | 1 |
| Zhang, M | 1 |
| Feng, T | 1 |
| Zhao, X | 1 |
| Tian, Y | 3 |
| Chen, T | 3 |
| Yang, L | 1 |
| Fan, X | 1 |
| Zhang, W | 2 |
| Feng, J | 1 |
| Yu, H | 2 |
| Yang, Y | 1 |
| Zhou, J | 1 |
| Yuan, Z | 3 |
| Shen, D | 1 |
| Li, H | 2 |
| Zhou, R | 1 |
| Liu, MJ | 1 |
| Wu, DF | 1 |
| Gao, H | 1 |
| Li, W | 1 |
| Shen, X | 1 |
| Di, B | 1 |
| Schmitt, MM | 1 |
| Fraemohs, L | 1 |
| Hackeng, TM | 1 |
| Weber, C | 1 |
| Koenen, RR | 1 |
| Zhu, XH | 1 |
| Yang, XF | 1 |
| Bao, XC | 1 |
| Gao, XQ | 1 |
| Qiu, YH | 1 |
| Wu, Z | 1 |
| Ji, XP | 1 |
| Li, HW | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Yang, H | 1 |
| Narita, I | 1 |
| Kon, V | 1 |
| Nakashiro, S | 1 |
| Matoba, T | 1 |
| Umezu, R | 1 |
| Koga, J | 1 |
| Tokutome, M | 1 |
| Katsuki, S | 1 |
| Nakano, K | 1 |
| Sunagawa, K | 1 |
| Egashira, K | 1 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Derosa, G | 2 |
| Salvadeo, SA | 1 |
| Shah, R | 1 |
| Fresco, C | 1 |
| Forst, T | 4 |
| Wilhelm, B | 1 |
| Pfützner, A | 4 |
| Fuchs, W | 1 |
| Lehmann, U | 1 |
| Schaper, F | 1 |
| Weber, M | 1 |
| Müller, J | 1 |
| Konrad, T | 2 |
| Hanefeld, M | 2 |
| Da-Wa, CR | 1 |
| Zhao, F | 1 |
| Qi, YF | 1 |
| Chen, LZ | 1 |
| Huo, Y | 1 |
| Nakaya, H | 2 |
| Summers, BD | 1 |
| Nicholson, AC | 1 |
| Gotto, AM | 1 |
| Hajjar, DP | 1 |
| Han, J | 1 |
| Thorp, E | 2 |
| Tabas, I | 2 |
| Fisher, M | 1 |
| Liu, Y | 2 |
| Liu, W | 2 |
| Xue, J | 1 |
| Shen, Y | 3 |
| Liang, X | 2 |
| Kishimoto, C | 2 |
| Han, SJ | 1 |
| Hur, KY | 1 |
| Kim, YS | 1 |
| Kang, ES | 1 |
| Kim, SI | 1 |
| Kim, MS | 1 |
| Kwak, JY | 1 |
| Kim, DJ | 1 |
| Choi, SH | 1 |
| Cha, BS | 1 |
| Lee, HC | 1 |
| Erdmann, E | 1 |
| Wilcox, R | 1 |
| Kanazawa, I | 1 |
| Yamaguchi, T | 1 |
| Yano, S | 1 |
| Yamamoto, M | 1 |
| Yamauchi, M | 1 |
| Kurioka, S | 1 |
| Sugimoto, T | 1 |
| Schöndorf, T | 1 |
| Subramanian, V | 1 |
| Golledge, J | 1 |
| Ijaz, T | 1 |
| Bruemmer, D | 1 |
| Daugherty, A | 1 |
| Nicholls, SJ | 2 |
| Tuzcu, EM | 2 |
| Wolski, K | 2 |
| Bayturan, O | 1 |
| Lavoie, A | 1 |
| Uno, K | 1 |
| Kupfer, S | 2 |
| Perez, A | 2 |
| Nesto, R | 2 |
| Nissen, SE | 2 |
| Takemoto, M | 1 |
| Yokote, K | 1 |
| Hiuge-Shimizu, A | 1 |
| Maeda, N | 1 |
| Hirata, A | 3 |
| Nakatsuji, H | 1 |
| Nakamura, K | 1 |
| Okuno, A | 1 |
| Kihara, S | 1 |
| Funahashi, T | 1 |
| Shimomura, I | 1 |
| Császár, A | 1 |
| Kawamori, R | 1 |
| Plutzky, J | 1 |
| Yin, A | 1 |
| Xiao, Y | 1 |
| Zhao, Y | 1 |
| Vucic, E | 1 |
| Dickson, SD | 1 |
| Calcagno, C | 1 |
| Rudd, JH | 1 |
| Moshier, E | 1 |
| Hayashi, K | 1 |
| Mounessa, JS | 1 |
| Roytman, M | 1 |
| Moon, MJ | 1 |
| Lin, J | 1 |
| Tsimikas, S | 1 |
| Fisher, EA | 2 |
| Nicolay, K | 1 |
| Fuster, V | 1 |
| Fayad, ZA | 1 |
| Tawakol, A | 1 |
| Finn, AV | 2 |
| Maffioli, P | 1 |
| Liu, CS | 1 |
| Chang, CC | 1 |
| Du, YC | 1 |
| Chang, FR | 1 |
| Wu, YC | 1 |
| Chang, WC | 1 |
| Hsieh, TJ | 1 |
| Avogaro, A | 1 |
| Federici, M | 1 |
| Betteridge, J | 1 |
| Bonadonna, R | 1 |
| Campbell, IW | 1 |
| Schernthaner, GH | 1 |
| Staels, B | 2 |
| Farinaro, E | 1 |
| Crepaldi, G | 1 |
| Blankfield, RP | 1 |
| Hennuyer, N | 1 |
| Tailleux, A | 1 |
| Torpier, G | 1 |
| Mezdour, H | 1 |
| Fruchart, JC | 1 |
| Fiévet, C | 2 |
| Carreón-Torres, E | 1 |
| Juárez-Meavepeña, M | 1 |
| Cardoso-Saldaña, G | 1 |
| Gómez, CH | 1 |
| Franco, M | 1 |
| Luc, G | 1 |
| Juárez-Oropeza, MA | 1 |
| Pérez-Méndez, O | 1 |
| Hohberg, C | 1 |
| Fuellert, SD | 1 |
| Lübben, G | 1 |
| Löbig, M | 1 |
| Weber, MM | 2 |
| Sachara, C | 1 |
| Gottschall, V | 1 |
| Os, I | 1 |
| Szapary, PO | 1 |
| Bloedon, LT | 1 |
| Samaha, FF | 1 |
| Duffy, D | 1 |
| Wolfe, ML | 1 |
| Soffer, D | 1 |
| Reilly, MP | 1 |
| Chittams, J | 1 |
| Rader, DJ | 1 |
| Martens, FM | 1 |
| Visseren, FL | 1 |
| de Koning, EJ | 1 |
| Rabelink, TJ | 1 |
| Trogan, E | 1 |
| Feig, JE | 1 |
| Dogan, S | 1 |
| Rothblat, GH | 1 |
| Angeli, V | 1 |
| Tacke, F | 1 |
| Randolph, GJ | 1 |
| Game, BA | 2 |
| He, L | 2 |
| Jarido, V | 1 |
| Nareika, A | 2 |
| Jaffa, AA | 1 |
| Lopes-Virella, MF | 1 |
| Huang, Y | 2 |
| Ríos-Vázquez, R | 1 |
| Marzoa-Rivas, R | 1 |
| Gil-Ortega, I | 1 |
| Kaski, JC | 1 |
| Kusuyama, T | 1 |
| Omura, T | 1 |
| Nishiya, D | 1 |
| Enomoto, S | 1 |
| Matsumoto, R | 1 |
| Takeuchi, K | 1 |
| Yoshikawa, J | 1 |
| Yoshiyama, M | 1 |
| Joner, M | 1 |
| Farb, A | 1 |
| Cheng, Q | 1 |
| Acampado, E | 1 |
| Burke, AP | 1 |
| Skorija, K | 1 |
| Creighton, W | 1 |
| Kolodgie, FD | 1 |
| Gold, HK | 1 |
| Virmani, R | 1 |
| Garvey, WT | 1 |
| Ruiz, E | 1 |
| Redondo, S | 1 |
| Gordillo-Moscoso, A | 1 |
| Tejerina, T | 1 |
| Igarashi, M | 2 |
| Jimbu, Y | 2 |
| Kimura, M | 1 |
| Yamaguchi, H | 2 |
| Tominaga, M | 2 |
| Giugliano, D | 1 |
| Esposito, K | 1 |
| Kida, Y | 1 |
| Sato, T | 1 |
| Kuriakose, G | 1 |
| Shah, YM | 1 |
| Gonzalez, FJ | 1 |
| Glintborg, D | 1 |
| Højlund, K | 1 |
| Andersen, M | 1 |
| Henriksen, JE | 1 |
| Beck-Nielsen, H | 1 |
| Handberg, A | 1 |
| Cho, LW | 1 |
| Atkin, SL | 1 |
| Wild, RA | 1 |
| Ohman, MK | 1 |
| Obimba, CI | 1 |
| Wright, AP | 1 |
| Warnock, M | 1 |
| Lawrence, DA | 1 |
| Eitzman, DT | 1 |
| Stojanovska, L | 1 |
| Honisett, SY | 1 |
| Komesaroff, PA | 1 |
| Steg, PG | 1 |
| Marre, M | 1 |
| Jure, H | 1 |
| De Larochellière, R | 1 |
| Staniloae, CS | 1 |
| Mavromatis, K | 1 |
| Saw, J | 1 |
| Hu, B | 1 |
| Lincoff, AM | 1 |
| Rizos, CV | 1 |
| Liberopoulos, EN | 1 |
| Mikhailidis, DP | 1 |
| Elisaf, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Pioglitazone on Insulin Resistance, Insulin Secretion and Atherosclerosis in Renal Allograft Recipients Without History of Diabetes[NCT00598013] | 83 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| A Double-Blind, Randomized, Comparator-Controlled Study In Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultr[NCT00225277] | Phase 3 | 547 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus[NCT00633282] | Phase 2 | 184 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Study on the Effects of Peroxisome Proliferators Activated Receptor-γ Agonists on Certain Biochemical and Inflammatory Markers in Patients With Metabolic Syndrome[NCT00926341] | Phase 4 | 110 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | Participants (Number) |
|---|---|
| Pioglitazone QD | 5 |
| Glimepiride QD | 6 |
Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | Participants (Number) |
|---|---|
| Pioglitazone QD | 40 |
| Glimepiride QD | 41 |
Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone QD | 11 |
| Glimepiride QD | 13 |
The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)
| Intervention | Percent volume (Least Squares Mean) | |
|---|---|---|
| Baseline | Nominal Change from Baseline | |
| Glimepiride QD | 217.619 | -1.480 |
| Pioglitazone QD | 206.579 | -5.528 |
The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)
| Intervention | Percent volume (Least Squares Mean) | |
|---|---|---|
| Baseline | Nominal Change from Baseline | |
| Glimepiride QD | 40.016 | 0.725 |
| Pioglitazone QD | 40.592 | -0.161 |
The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure. (NCT00225277)
Timeframe: Up to 72 weeks
| Intervention | Number of Events (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonfatal Myocardial Infarction | Nonfatal Stroke | Coronary Revascularization: PCI/CABG counted once | Coronary Revascularization: PCI | Coronary Revascularization: CABG | Carotid Endarterectomy/Stenting | Hospitalization for Unstable Angina | CHF Hospitalization: new/exacerbated counted once | Hospitalization for New CHF | Hospitalization for Exacerbated CHF | Noncardiovascular Mortality | Cardiovascular Mortality | Composite Endpoint A | Composite Endpoint B | Composite Endpoint C | |
| Glimepiride QD | 4 | 1 | 30 | 28 | 2 | 0 | 2 | 5 | 2 | 3 | 1 | 1 | 6 | 41 | 13 |
| Pioglitazone QD | 2 | 0 | 29 | 25 | 5 | 1 | 4 | 4 | 4 | 0 | 0 | 3 | 5 | 40 | 11 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
15 reviews available for pioglitazone and Atherogenesis
| Article | Year |
|---|---|
Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Development; Humans; Hydroxymethylglutaryl-CoA Reduct | 2020 |
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.
Topics: Adipose Tissue; Apolipoproteins; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Humans; Hy | 2008 |
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diab | 2009 |
Pioglitazone and mechanisms of CV protection.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angi | 2010 |
[Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice].
Topics: Animals; Atherosclerosis; Diet, Atherogenic; Hypoglycemic Agents; Mice; Mice, Knockout; Pioglitazone | 2010 |
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Humans; | 2010 |
[Prevention, treatment and management of inflammation in atherosclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Biomarkers; C-Reactive Protein; Chronic D | 2011 |
[Anti-atherosclerotic effect of pioglitazone--the first evidence of the role of triglyceride/HDL ratio].
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Body F | 2011 |
Macrovascular effects and safety issues of therapies for type 2 diabetes.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Pro | 2011 |
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Topics: Atherosclerosis; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Ins | 2012 |
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Hu | 2006 |
Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatt | 2007 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exerci | 2007 |
The anti-atherogenic effects of thiazolidinediones.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diab | 2007 |
Pleiotropic effects of thiazolidinediones.
Topics: Atherosclerosis; Body Fat Distribution; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; | 2008 |
12 trials available for pioglitazone and Atherogenesis
| Article | Year |
|---|---|
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Carotid Artery, Common | 2008 |
Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients.
Topics: Adiponectin; Adult; Atherosclerosis; Carotid Arteries; Disease Progression; Female; Glucose Intolera | 2010 |
Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus.
Topics: Aged; Atherosclerosis; Biomarkers; Blood Glucose; Body Weight; Bone Density; Collagen; Diabetes Mell | 2010 |
Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression o
Topics: Atherosclerosis; Cholesterol, HDL; Coronary Artery Disease; Coronary Stenosis; Diabetes Mellitus, Ty | 2011 |
[Evidences demonstrating the effects of prevention of major adverse cardiovascular events and anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive study and PERISCOPE study].
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycem | 2011 |
Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; Biomarkers; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Humans; Hypo | 2005 |
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Atherosclerosis; Biomarkers; Body Weight; Cholesterol, HDL; Cholesterol, L | 2006 |
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Atherosclerosis; Biomarkers; Body Weight; Cholesterol, HDL; Cholesterol, L | 2006 |
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Atherosclerosis; Biomarkers; Body Weight; Cholesterol, HDL; Cholesterol, L | 2006 |
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Atherosclerosis; Biomarkers; Body Weight; Cholesterol, HDL; Cholesterol, L | 2006 |
Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.
Topics: Adiponectin; Atherosclerosis; Brachial Artery; C-Reactive Protein; Cross-Over Studies; Diabetes Mell | 2005 |
Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders.
Topics: Aged; Atherosclerosis; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Female; Glucose; Hom | 2007 |
Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.
Topics: Antigens, CD; Atherosclerosis; Biomarkers; Blood Glucose; Body Composition; C-Reactive Protein; Dipe | 2008 |
Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, | 2008 |
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum | 2008 |
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum | 2008 |
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum | 2008 |
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum | 2008 |
43 other studies available for pioglitazone and Atherogenesis
| Article | Year |
|---|---|
Leoligin, the Major Lignan from Edelweiss (Leontopodium nivale subsp. alpinum), Promotes Cholesterol Efflux from THP-1 Macrophages.
Topics: Asteraceae; Atherosclerosis; ATP-Binding Cassette Transporters; Biological Transport; Blotting, West | 2016 |
Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Matr | 2022 |
Encapsulation of Pioglitazone into Polymer-Nanoparticles for Potential Treatment of Atherosclerotic Diseases.
Topics: Atherosclerosis; Humans; Macrophages; Nanoparticles; Pioglitazone; Polymers | 2023 |
An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Biomimetic Materials; Cytokin | 2019 |
Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients.
Topics: Adult; Atherosclerosis; Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Dr | 2017 |
Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An
Topics: Animals; Atherosclerosis; Calcinosis; Fluorodeoxyglucose F18; Hypoglycemic Agents; Inflammation; Mal | 2018 |
Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Atherosclerosis; Cells, Cultured; Hypoglycemic Agents | 2017 |
Pioglitazone attenuates aging-related disorders in aged apolipoprotein E deficient mice.
Topics: Age Factors; Aging; Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Atherosclerosi | 2018 |
Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Diabetes Complications; Diabetes Melli | 2017 |
Atherogenic mononuclear cell recruitment is facilitated by oxidized lipoprotein-induced endothelial junctional adhesion molecule-A redistribution.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Cell Adhesion Molecules; Cell | 2014 |
Effect of pioglitazone combined with simvastatin on the CD40-CD40 ligand system in rabbits with atherosclerosis.
Topics: Animals; Atherosclerosis; CD40 Antigens; CD40 Ligand; Hypolipidemic Agents; Lipids; Male; Pioglitazo | 2015 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE-/- Mice.
Topics: Administration, Intravenous; Angiotensin II; Animals; Apolipoproteins E; Atherosclerosis; Brachiocep | 2016 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2008 |
Pioglitazone vs glimepiride in the PERISCOPE trial.
Topics: Atherosclerosis; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; H | 2008 |
Pioglitazone vs glimepiride in the PERISCOPE trial.
Topics: Atherosclerosis; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-C | 2008 |
[Role of adiponectin and its receptors in anti-atherosclerotic effects of pioglitazone on ApoE knocked out mice].
Topics: Adiponectin; Animals; Apolipoproteins E; Atherosclerosis; Hypoglycemic Agents; Male; Mice; Mice, Inb | 2009 |
Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone.
Topics: Animals; Atherosclerosis; Blotting, Western; Cholesterol, HDL; Cholesterol, LDL; Hypoglycemic Agents | 2009 |
Differential effects of pioglitazone on advanced atherosclerotic lesions.
Topics: Animals; Atherosclerosis; Humans; Hypoglycemic Agents; Mice; Necrosis; Pioglitazone; PPAR gamma; Rec | 2009 |
Pioglitazone modulates the balance of effector and regulatory T cells in apolipoprotein E deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cytokines; Disease Progression; Flow Cytometry; Forkhea | 2011 |
Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}.
Topics: Angiotensin II; Animals; Aorta; Atherosclerosis; Cells, Cultured; Chemokine CCL2; Female; Hypoglycem | 2010 |
Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue, White; Animals; Apolipoproteins E; Atheroscle | 2011 |
Antiatherogenic effect of pioglitazone on uremic apolipoprotein E knockout mice by modulation of the balance of regulatory and effector T cells.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Cytokines; Hypoglycemic Agents; Mal | 2011 |
Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortography; Atherosclerosis; Biomarkers; Contrast Media; | 2011 |
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art | 2011 |
2-hydroxy-4'-methoxychalcone inhibits proliferation and inflammation of human aortic smooth muscle cells by increasing the expression of peroxisome proliferator-activated receptor gamma.
Topics: Aorta; Atherosclerosis; Cell Cycle; Cell Proliferation; Chalcones; Drug Synergism; Gene Expression R | 2012 |
Which is the eligible patient to be treated with pioglitazone? The expert view.
Topics: Algorithms; Animals; Atherosclerosis; Blood Glucose; Cardiotonic Agents; Diabetes Mellitus, Type 2; | 2011 |
Blood pressure, fluid retention and the cardiovascular risk of drugs.
Topics: Antipsychotic Agents; Atherosclerosis; Blood Pressure; Cardiovascular System; Cyclooxygenase 2 Inhib | 2012 |
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Anima | 2005 |
Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Hypoglycemic Agents; Iodine Radioisotopes; Lipoprotein | 2005 |
[PPARgamma agonists--antidiabetics with positive effects on cardiovascular risk?].
Topics: Albuminuria; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Glucose; Humans; Hypoglycemic | 2005 |
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; AT | 2006 |
Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice.
Topics: Animals; Aorta; Atherosclerosis; Cells, Cultured; Connective Tissue Growth Factor; Diet, Atherogenic | 2007 |
Effects of treatment for diabetes mellitus on circulating vascular progenitor cells.
Topics: Actins; Adult; Atherosclerosis; Blood Glucose; Cell Proliferation; Diabetes Complications; Diabetes | 2006 |
Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1.
Topics: Administration, Oral; Animals; Atherosclerosis; Cell Proliferation; Cells, Cultured; Chemokine CCL2; | 2007 |
Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques.
Topics: Animals; Atherosclerosis; Disease Models, Animal; Disease Progression; Gene Expression; Matrix Metal | 2006 |
Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway.
Topics: Activin Receptors; Activin Receptors, Type I; Aged; Anaplastic Lymphoma Kinase; Apoptosis; Atheroscl | 2007 |
Pioglitazone vs glimepiride and carotid intima-media thickness.
Topics: Atherosclerosis; Carotid Arteries; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglyce | 2007 |
Pioglitazone vs glimepiride and carotid intima-media thickness.
Topics: Albuminuria; Atherosclerosis; Carotid Arteries; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Huma | 2007 |
Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice.
Topics: Animals; Apoptosis; Atherosclerosis; Cell Survival; Cholesterol; Diabetes Mellitus, Type 2; Female; | 2007 |
Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: counterpoint.
Topics: Adult; Atherosclerosis; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hyperlipidemias; Metfor | 2008 |
Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice.
Topics: Adiponectin; Animals; Apolipoproteins E; Atherosclerosis; Inflammation; Intra-Abdominal Fat; Leptin; | 2008 |
Does PERISCOPE provide a new perspective on diabetic treatment?
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Sulfonylurea | 2008 |